Dr.Β RaajitΒ Rampal
MD, PhD
Associate Member & Director, Center for Hematologic Malignancies
corporate_fareMemorial Sloan Kettering Cancer Center, New York
Raajit Rampal
MD, PhD
Dr. Raajit K. Rampal is a physician-scientist and Associate Member at Memorial Sloan Kettering Cancer Center (MSKCC), where he serves as Director of the Center for Hematologic Malignancies and Director of the Myeloproliferative Neoplasms (MPN) and Rare Hematologic Malignancies Program. He holds an MD and a PhD in Molecular and Cellular Biology from Stony Brook University, and is board-certified in Internal Medicine, Medical Oncology, and Hematology.
With over 17 years of clinical and research experience at MSKCC, Dr. Rampal specialises in the treatment of myeloproliferative neoplasms β including myelofibrosis, polycythemia vera, and essential thrombocythemia β as well as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), and other rare blood cancers. His laboratory research focuses on the genetic events that drive MPN pathogenesis and transformation to acute leukaemia, with a translational goal of developing novel targeted therapies for patients. Dr. Rampal actively leads and participates in phase 1 and phase 2 clinical trials investigating JAK inhibitors and other molecularly targeted agents. He has co-authored over 150 peer-reviewed publications and is a regular presenter at the American Society of Hematology (ASH) Annual Meeting. His approach to care is personalised, considering each patient's specific disease biology, prior treatments, and family circumstances.
CancerFax can coordinate medical-record review and second-opinion support for international patients seeking a consultation with Dr. Rampal at Memorial Sloan Kettering Cancer Center.
Why Consider Dr. Raajit Rampal?
Dr. Rampal is one of the world's foremost authorities on myeloproliferative neoplasms and myeloid malignancies. Patients with complex MPN, myelofibrosis, AML evolved from MPN, or rare haematological conditions travel from across the globe to seek his expertise at MSKCC.
Areas of Specialisation
Dr. Rampal's clinical and research focus spans myeloproliferative neoplasms, myeloid leukaemia, and rare haematologic malignancies.
Dr. Rampal's practice centres on the full spectrum of myeloproliferative neoplasms β from polycythemia vera and essential thrombocythemia to myelofibrosis and MPN-related acute myeloid leukaemia. He combines deep molecular expertise with broad clinical experience in AML, MDS, and rare blood cancers.
Myeloproliferative Neoplasms (MPN)
Comprehensive management of MPN including disease risk stratification, symptom-directed therapy, JAK inhibitor treatment, and monitoring for disease progression or leukaemic transformation.
- arrow_rightPrimary and secondary myelofibrosis management
- arrow_rightJAK inhibitor therapy including ruxolitinib and momelotinib
- arrow_rightAnaemia management in myelofibrosis
- arrow_rightAssessment for stem cell transplantation eligibility
- arrow_rightRisk-adapted treatment planning for PV and ET
- arrow_rightCytoreductive therapy and phlebotomy management
- arrow_rightMonitoring for transformation to myelofibrosis or AML
Myeloid Leukaemia & Related Disorders
Expert management of AML arising de novo and from prior MPN or MDS, along with myelodysplastic syndrome and systemic mastocytosis.
- arrow_rightAML arising from MPN or MDS (secondary AML)
- arrow_rightMolecularly targeted therapy based on somatic mutation profile
- arrow_rightPhase 1 and phase 2 investigational therapy trials
- arrow_rightTransplant-eligibility assessment and referral coordination
- arrow_rightRisk stratification and individualised treatment planning
- arrow_rightSupportive care including transfusion management
- arrow_rightTargeted therapy where molecularly applicable
- arrow_rightSystemic mastocytosis diagnosis and management
- arrow_rightHairy cell leukaemia and related rare conditions
- arrow_rightComplex cases reviewed within MSKCC multidisciplinary team
Procedures & Clinical Approaches
Treatment services and clinical pathways offered by Dr. Rampal at MSKCC
Dr. Rampal offers evidence-based and investigational treatment approaches for patients with MPN, myeloid leukaemia, and related disorders. His clinical services span front-line treatment planning, JAK inhibitor therapy, participation in novel clinical trials, and second-opinion consultations.
JAK Inhibitor & Targeted Therapy
Targeted TherapyDr. Rampal is an internationally recognised expert in JAK inhibitor therapy for myelofibrosis and MPN. He provides molecularly guided treatment selection based on mutation profiling and disease stage.
Clinical Trial Participation
Medical OncologyDr. Rampal leads and co-investigates multiple phase 1 and phase 2 trials at MSKCC for patients with MPN and myeloid malignancies.
Haematology Diagnostic Procedures
DiagnosisComprehensive diagnostic evaluation and monitoring for blood and bone marrow disorders.
Second Opinion Consultation
Second OpinionDr. Rampal provides expert second opinions for patients with MPN, AML, MDS, and rare haematologic conditions. International patients can submit reports through CancerFax for review and coordination.
Research & Publications
Peer-reviewed contributions in MPN pathogenesis, JAK inhibitor therapy, and myeloid malignancy
Dr. Rampal has co-authored over 150 peer-reviewed articles and is one of the most cited researchers in the field of myeloproliferative neoplasms. His laboratory at MSKCC uses primary patient samples to study the genetic drivers of MPN and leukemic transformation, with a direct translational focus on developing novel targeted treatments.
Dr. Rampal combines active laboratory research with clinical practice, meaning patients at MSKCC benefit directly from his ongoing work to develop novel targeted therapies for MPN and myeloid leukaemia.
Education & Training
Dr. Rampal completed his undergraduate, medical, and doctoral training at Stony Brook University, followed by residency at the University of Chicago and fellowship and postdoctoral training at Memorial Sloan Kettering Cancer Center.
Clinical Experience
Dr. Rampal has spent his entire post-training career at Memorial Sloan Kettering Cancer Center, where he has progressed to hold concurrent leadership roles directing the Centre for Hematologic Malignancies and the MPN and Rare Hematologic Malignancies Program.
Languages & International
Dr. Rampal consults in the following language.
CancerFax can coordinate professional medical interpreter support for international patients requiring assistance in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Rampal.
How CancerFax Helps You Access Dr. Raajit Rampal
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Raajit Rampal's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Raajit Rampal's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Raajit Rampal before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Raajit Rampal's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Raajit Rampal's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Raajit Rampal's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Raajit Rampal
Dr. Rampal specialises in myeloproliferative neoplasms (MPN) including myelofibrosis, polycythemia vera, and essential thrombocythemia, as well as acute myeloid leukaemia (AML) β particularly AML arising from prior MPN or MDS β myelodysplastic syndrome (MDS), systemic mastocytosis, and other rare haematologic malignancies.
Yes. Dr. Rampal at Memorial Sloan Kettering Cancer Center offers second-opinion consultations, and virtual visits are available through MSKCC. CancerFax can help international patients organise and submit their medical reports β including pathology, bone marrow reports, imaging, and mutation studies β and coordinate the next steps with the hospital, subject to availability and case acceptance.
Submit your medical records through the CancerFax upload portal. The CancerFax team will review the documents, prepare a structured medical summary, and coordinate submission and communication with Memorial Sloan Kettering Cancer Center on your behalf. The timeline and format of the consultation depend on MSKCC's availability.
Dr. Rampal is one of the world's foremost experts in JAK inhibitor therapy for myelofibrosis and MPN. He has extensive experience with ruxolitinib, momelotinib, and investigational JAK inhibitor combinations, and he regularly presents advances in this area at the American Society of Hematology (ASH) Annual Meeting. He also leads clinical trials evaluating novel JAK inhibitor combinations at MSKCC.
Yes. Dr. Rampal actively leads and co-investigates multiple phase 1 and phase 2 clinical trials at MSKCC. These include studies of ruxolitinib plus abemaciclib, momelotinib combined with luspatercept, and novel investigational agents such as AJ1-11095 and DISC-0974 for patients with myelofibrosis and related conditions. Eligibility for any trial depends on individual clinical and molecular criteria.
Dr. Raajit Rampal is based at Memorial Sloan Kettering Cancer Center (MSKCC) at 1275 York Avenue, New York, NY 10065, USA. He serves as Associate Member and Director of the Center for Hematologic Malignancies and the MPN and Rare Hematologic Malignancies Program.
Connect with Raajit Rampal Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.